Division of Urology and Department of Pathology University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
BJU Int. 2011 Jan;107(1):46-52. doi: 10.1111/j.1464-410X.2010.09635.x. Epub 2010 Sep 29.
To evaluate the concordance transurethral resection of bladder tumour (TURBT) and radical cystectomy (RC) specimens with regard to the presence of lymphovascular invasion (LVI). Additionally, to evaluate the prognostic value of LVI in the prediction of lymph node metastases, overall survival, disease-specific survival and recurrence-free survival following RC.
The records of 487 patients who underwent RC at our institution between 1987 and 2008 were retrospectively reviewed and evaluated for the presence or absence of LVI as determined by pathological evaluation. The presence or absence of LVI was then evaluated on previous transrectal resection specimens of this cohort of patients undergoing RC. Cox regression and Kaplan-Meier analysis were undertaken to evaluate the contribution of LVI to various outcomes.
Of 474 patients with complete LVI data, 60 (12.3%) were found to have LVI at TURBT compared to 161 (33.1%) at RC. Although the presence of LVI at TURBT was more significantly associated with the presence of LVI at RC, only 42.9% of patients in whom LVI was documented at TURBT were found to harbour LVI at RC. The risk of nodal disease was higher in those patients with LVI at TURBT than in those with no evidence of LVI at TURBT (48.3% vs 25.0%, P < 0.001). Additionally, LVI at TURBT was associated with an increasing risk of pathological upstaging and the receipt of adjuvant chemotherapy. Survival analysis showed a significant decrement in overall and recurrence-free survival among those with LVI at TURBT compared to those with no evidence of LVI.
Lymphovascular invasion at TURBT provides useful prognostic information that should be incorporated into clinical decision-making, particularly with regard to cystectomy for nonmuscle-invasive carcinoma and the administration of neoadjuvant chemotherapy.
评估经尿道膀胱肿瘤切除术(TURBT)和根治性膀胱切除术(RC)标本中存在脉管侵犯(LVI)的一致性。此外,评估 LVI 在预测 RC 后淋巴结转移、总生存、疾病特异性生存和无复发生存方面的预后价值。
回顾性分析 1987 年至 2008 年在我院接受 RC 的 487 例患者的病历,并通过病理评估评估 LVI 的存在或不存在。然后评估该 RC 患者队列的先前经直肠切除术标本中 LVI 的存在。采用 Cox 回归和 Kaplan-Meier 分析评估 LVI 对各种结局的贡献。
在 474 例有完整 LVI 数据的患者中,60 例(12.3%)在 TURBT 时发现 LVI,161 例(33.1%)在 RC 时发现 LVI。尽管 TURBT 时存在 LVI 与 RC 时存在 LVI 更显著相关,但在 TURBT 时记录有 LVI 的患者中,只有 42.9%的患者在 RC 时发现 LVI。在 TURBT 时存在 LVI 的患者中,发生淋巴结疾病的风险高于在 TURBT 时无 LVI 证据的患者(48.3%比 25.0%,P<0.001)。此外,TURBT 时的 LVI 与病理升级和接受辅助化疗的风险增加相关。生存分析显示,在 TURBT 时存在 LVI 的患者与无 LVI 证据的患者相比,总生存和无复发生存均显著下降。
TURBT 时的 LVI 提供了有用的预后信息,应纳入临床决策,特别是对于非肌肉浸润性癌的膀胱切除术和新辅助化疗的应用。